Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Fosun Pharma Partners with Clavis Bio in $362.5M Strategic Collaboration

Fineline Cube Dec 21, 2025
Company Deals

Leadingtac Raises RMB 200M Series B to Advance Protein Degradation Pipeline

Fineline Cube Dec 20, 2025
Company Deals

Baiyunshan to Acquire Zhejiang Pharma‑Industry for $500.5M, Expanding Distribution Network

Fineline Cube Dec 19, 2025
Company Deals

InSilico Medicine Debuts on HKEX in $2.3B IPO, Valuing AI Drug Platform at $1.5B

Fineline Cube Dec 18, 2025
Company Deals

Sirnaomics Partners on $42M Small Nucleic Acid Fund in Hangzhou

Fineline Cube Dec 18, 2025
Policy / Regulatory

China Mandates Specialty Departments in Primary Care by 2030

Fineline Cube Dec 18, 2025
Company Drug

BeOne Medicines Wins FDA Fast Track for GPC3 Bispecific in Liver Cancer

Fineline Cube Dec 21, 2025
Company Drug

TransThera NDA Accepted for Tinengotinib in Cholangiocarcinoma After FGFR Inhibitor

Fineline Cube Dec 20, 2025
Company Deals

Medim Science Raises Funds for Macrophage-Targeting Biologics in Cancer Therapy

Fineline Cube Sep 2, 2022

Hangzhou-based Medim Science, China’s first pharma firm focused on macrophage-targeting biologics, has reportedly raised tens...

Drug Medical Device

China’s Pharmaceutical Industry Sees Revenue Decline Amid Export Shifts

Fineline Cube Sep 2, 2022

China’s pharmaceutical manufacturing sector reported a 1.8% year-on-year (YOY) revenue decline to RMB 1.6 trillion...

Company Deals

Tibet Duo Rui and Nanjing Heron Forge Pharmaceutical Collaboration in China

Fineline Cube Sep 2, 2022

China-based Tibet Duo Rui Pharmaceutical Co., Ltd and Nanjing Heron Pharmaceutical Science and Technology Co.,...

Company Drug

CARsgen Therapeutics Launches GMP Manufacturing for CAR-T Cell Therapies in North Carolina

Fineline Cube Sep 2, 2022

China’s CARsgen Therapeutics Holdings Ltd (HKG: 2171), a chimeric antigen receptor (CAR)-T cell specialist, has...

Company Deals

MegaRobo and Danaher Life Sciences Partner on Lab Automation in China

Fineline Cube Sep 2, 2022

Beijing-based MegaRobo Technologies, a robotics and AI firm in life sciences, has partnered with Danaher...

Company Drug

Hengrui Medicine’s HRG2101 Inhaler Wins NMPA Approval for IPF Clinical Trial

Fineline Cube Sep 2, 2022

China’s Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) has received approval from the National Medical...

Company Deals

U Protech Secures Angel Financing for PROTAC and Molecular Glue Drug Pipeline

Fineline Cube Sep 2, 2022

U Protech, a Hangzhou-based biotech focused on next-generation protein degradation therapies, has raised tens of...

Company Deals Digital

J&J China, Tencent Launch Digital Rhinitis Platform “Love Nose e-Station”

Fineline Cube Sep 2, 2022

Johnson & Johnson’s (J&J, NYSE: JNJ) J&J China Self Care and China’s Tencent have launched...

Company Deals

Neukio Biotherapeutics Completes USD 50M Series A-1 Financing for iPSC-CAR-NK Therapy

Fineline Cube Sep 2, 2022

Shanghai-based Neukio Biotherapeutics, a developer of iPSC-derived chimeric antigen receptor natural killer (CAR-NK) cell therapies,...

Company Deals

Acorda Therapeutics Licenses Preclinical Drug Nepicastat to China’s Asieris

Fineline Cube Sep 2, 2022

US-based Acorda Therapeutics Inc. (Nasdaq: ACOR) announced a licensing agreement with China’s Asieris Pharmaceuticals for...

Policy / Regulatory

SAMR Issues New Rules for Online Drug Sales in China

Fineline Cube Sep 2, 2022

China’s State Administration for Market Regulation (SAMR) has released the “Measures for the Supervision and...

Policy / Regulatory

NMPA Designates Shijiazhuang Airport as Drug Import Port for Narcotics, Psychotropics

Fineline Cube Sep 2, 2022

China’s National Medical Products Administration (NMPA) has designated Shijiazhuang Airport in Hebei Province as an...

Company

Henlius Biotech Plans US Bridging Study for Serplulimab in ES-SCLC

Fineline Cube Sep 1, 2022

Shanghai Henlius Biotech (HKG: 2696) is advancing its checkpoint inhibitor serplulimab toward the U.S. market,...

Company Drug

RedCloud Bio Doses First Patient in H002 EGFR TKI Phase I/IIa Trial for NSCLC

Fineline Cube Sep 1, 2022

Shanghai-based RedCloud Bio announced that the first patient has been dosed in a Phase I/IIa...

Company Drug

Lepu Biopharma’s MRG002 Earns FDA Orphan Drug Status for Gastric Cancer

Fineline Cube Sep 1, 2022

China’s Lepu Biopharma Co., Ltd (HKG: 2157) announced that the U.S. FDA has granted orphan...

Drug Policy / Regulatory

CDE Releases 62nd Batch of Chemical Generic References, Updates 39 Specifications

Fineline Cube Sep 1, 2022

The Center for Drug Evaluation (CDE) has released the 62nd batch of chemical generic reference...

Company Drug

Jacobio Pharmaceuticals Doses First Patient in JAB-21822 Phase IIa Trial for KRAS G12C NSCLC

Fineline Cube Sep 1, 2022

China’s Jacobio Pharmaceuticals Group Co., Ltd (HKG: 1167) announced the first patient dosed in a...

Company Deals

Novartis Partners with Beijing’s Changping District to Expand Drug Development

Fineline Cube Sep 1, 2022

Swiss pharma giant Novartis (NYSE: NVS) has partnered with Beijing’s Changping district government to expand...

Company

GenScript Biotech’s H1 2022 Revenue Rises 32.7% on Carvykti CAR-T Sales

Fineline Cube Sep 1, 2022

Nanjing-based GenScript Biotech, a biopharma and contract research firm, reported a 32.7% year-on-year (YOY) revenue...

Company Deals

Mayo Clinic Launches Mayflower BioVentures to Accelerate Cell and Gene Therapies

Fineline Cube Sep 1, 2022

The Mayo Clinic, a leading US hospital group, has launched Mayflower BioVentures, a cell and...

Posts pagination

1 … 563 564 565 … 600

Recent updates

  • Fosun Pharma Partners with Clavis Bio in $362.5M Strategic Collaboration
  • BeOne Medicines Wins FDA Fast Track for GPC3 Bispecific in Liver Cancer
  • BeOne Medicines Names Dual Presidents in Leadership Overhaul
  • Leadingtac Raises RMB 200M Series B to Advance Protein Degradation Pipeline
  • TransThera NDA Accepted for Tinengotinib in Cholangiocarcinoma After FGFR Inhibitor
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Fosun Pharma Partners with Clavis Bio in $362.5M Strategic Collaboration

Company Drug

BeOne Medicines Wins FDA Fast Track for GPC3 Bispecific in Liver Cancer

Company

BeOne Medicines Names Dual Presidents in Leadership Overhaul

Company Deals

Leadingtac Raises RMB 200M Series B to Advance Protein Degradation Pipeline

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.